Hidradenitis Suppurativa Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

October 20 12:30 2021
Hidradenitis Suppurativa Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s ‘Hidradenitis Suppurativa Market Insights, Epidemiology and Market Forecast-2030’ report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.

DelveInsight’s “Hidradenitis Suppurativa Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Hidradenitis Suppurativa pipeline landscapes. It comprises Hidradenitis Suppurativa pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Hidradenitis Suppurativa therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Hidradenitis Suppurativa pipeline products.     

Some of the key takeaways of the Hidradenitis Suppurativa Pipeline Report  

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as InflaRx, Novartis, ChemoCentryx, UCB Biopharma, Janssen Pharmaceutical / XBiotech, Incyte Corporation, etc., are developing therapies for the treatment of Hidradenitis Suppurativa.

  • Emerging therapies such as IFX-1, CJM112, Cosentyx (Secukinumab), INCB054707, Bimekizumab, Bermekimab (MABp1), Avacopan, are expected to have a significant impact on the Hidradenitis Suppurativa market in the coming years.

Get an overview of pipeline landscape @ Hidradenitis Suppurativa Clinical Trials Analysis 

Hidradenitis Suppurativa Overview

Hidradenitis Suppurativa (HS) is a complex dermatological disease characterized by recurrent painful nodules and suppuration in areas such as the axilla and groin. It is also known as Acne inversa and there is no biological or pathological test to facilitate diagnosis, it can be defined by its clinical features and its chronicity. 

Hidradenitis Suppurativa Emerging Drugs

  1. IFX-1: InflaRx

  2. Cosentyx/Secukinumab: Novartis

  3. Avacopan: ChemoCentryx

  4. Bimekizumab: UCB Biopharma

  5. Bermekimab (MABp1): Janssen Pharmaceutica l / XBiotech

  6. INCB054707: Incyte Corporation

For further information, refer to the detailed report @ Hidradenitis Suppurativa Pipeline Therapeutics 

Scope of Hidradenitis Suppurativa Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: InflaRx, Novartis Pharmaceuticals, Incyte Corporation, UCB Biopharma S.P.R.L., Janssen Pharmaceutical, Pfizer, and others.

  • Pipeline Therapies: IFX-1, Cosentyx (Secukinumab), INCB054707, Bimekizumab, Bermekimab (MABp1), Avacopan, and others.

Table of Contents

1

Hidradenitis Suppurativa Report Introduction

2

Hidradenitis Suppurativa Executive Summary

3

Hidradenitis Suppurativa Overview

4

Hidradenitis Suppurativa- Analytical Perspective In-depth Commercial Assessment

5

Hidradenitis Suppurativa Pipeline Therapeutics

6

Hidradenitis Suppurativa Late Stage Products (Phase II/III)

7

Hidradenitis Suppurativa Mid Stage Products (Phase II)

8

Hidradenitis Suppurativa Early Stage Products (Phase I)

9

Hidradenitis Suppurativa Preclinical Stage Products

10

Hidradenitis Suppurativa Therapeutics Assessment

11

Hidradenitis Suppurativa Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Hidradenitis Suppurativa Key Companies

14

Hidradenitis Suppurativa Key Products

15

Hidradenitis Suppurativa Unmet Needs

16 

Hidradenitis Suppurativa Market Drivers and Barriers

17

Hidradenitis Suppurativa Future Perspectives and Conclusion

18

Hidradenitis Suppurativa Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Hidradenitis Suppurativa Drugs Pipeline Report.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/